PRO UNLIMITED for SANOFI-AVENTIS U S INC
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
FDA related legislation;DTC consumer advertising;authorized generics/patents and Hatch-Waxman reform; follow-on biologics (biosimilars); manufacturing pricing or rebate obligations and patient access under government programs such as Medicaid and Medicare; animals in research;military and veterans health care programs involving prescription drug medications prescription drug reimportation CMS reimbursement and coverage; corporate tax legislation and legal reform issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN LABELLE New | — |
Budget/Appropriations BUD
FDA related legislation;DTC consumer advertising;authorized generics/patents and Hatch-Waxman reform; follow-on biologics (biosimilars); manufacturing pricing or rebate obligations and patient access under government programs such as Medicaid and Medicare; animals in research;military and veterans health care programs involving prescription drug medications prescription drug reimportation CMS reimbursement and coverage; corporate tax legislation and legal reform issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN LABELLE New | — |
Chemicals/Chemical Industry CHM
FDA related legislation;DTC consumer advertising;authorized generics/patents and Hatch-Waxman reform; follow-on biologics (biosimilars); manufacturing pricing or rebate obligations and patient access under government programs such as Medicaid and Medicare; animals in research;military and veterans health care programs involving prescription drug medications prescription drug reimportation CMS reimbursement and coverage; corporate tax legislation and legal reform issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN LABELLE New | — |
Medicare/Medicaid MMM
FDA related legislation;DTC consumer advertising;authorized generics/patents and Hatch-Waxman reform; follow-on biologics (biosimilars); manufacturing pricing or rebate obligations and patient access under government programs such as Medicaid and Medicare; animals in research;military and veterans health care programs involving prescription drug medications prescription drug reimportation CMS reimbursement and coverage; corporate tax legislation and legal reform issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN LABELLE New | — |
Animals ANI
FDA related legislation;DTC consumer advertising;authorized generics/patents and Hatch-Waxman reform; follow-on biologics (biosimilars); manufacturing pricing or rebate obligations and patient access under government programs such as Medicaid and Medicare; animals in research;military and veterans health care programs involving prescription drug medications prescription drug reimportation CMS reimbursement and coverage; corporate tax legislation and legal reform issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN LABELLE New | — |
Medical/Disease Research/Clinical Labs MED
FDA related legislation;DTC consumer advertising;authorized generics/patents and Hatch-Waxman reform; follow-on biologics (biosimilars); manufacturing pricing or rebate obligations and patient access under government programs such as Medicaid and Medicare; animals in research;military and veterans health care programs involving prescription drug medications prescription drug reimportation CMS reimbursement and coverage; corporate tax legislation and legal reform issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN LABELLE New | — |
Advertising ADV
FDA related legislation;DTC consumer advertising;authorized generics/patents and Hatch-Waxman reform; follow-on biologics (biosimilars); manufacturing pricing or rebate obligations and patient access under government programs such as Medicaid and Medicare; animals in research;military and veterans health care programs involving prescription drug medications prescription drug reimportation CMS reimbursement and coverage; corporate tax legislation and legal reform issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN LABELLE New | — |
Copyright/Patent/Trademark CPT
FDA related legislation;DTC consumer advertising;authorized generics/patents and Hatch-Waxman reform; follow-on biologics (biosimilars); manufacturing pricing or rebate obligations and patient access under government programs such as Medicaid and Medicare; animals in research;military and veterans health care programs involving prescription drug medications prescription drug reimportation CMS reimbursement and coverage; corporate tax legislation and legal reform issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN LABELLE New | — |
Health Issues HCR
FDA related legislation;DTC consumer advertising;authorized generics/patents and Hatch-Waxman reform; follow-on biologics (biosimilars); manufacturing pricing or rebate obligations and patient access under government programs such as Medicaid and Medicare; animals in research;military and veterans health care programs involving prescription drug medications prescription drug reimportation CMS reimbursement and coverage; corporate tax legislation and legal reform issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN LABELLE New | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| SANOFI-AVENTIS | France | France | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.